Flow cytometry was first used to isolate a stem cell when the laboratory of Dr. Irving Weissman reported the prospective identification of mouse hematopoietic stem cells in 1986. In 2008, flow cytometry still sets the standard for cell enrichment. Thus, a state of the art flow cytometry core is critical for the isolation of solid tumor and leukemia stem cells for the 3 projects of this proposal. When working with human specimens obtained from the pathologist, one cannot predict with certainty when a specimen will arrive. This is predominantly because of the inherent uncertainty of surgical scheduling and issues that arise during an operation. The successful isolation of cancer stem cells is dependent upon the speed in which a tumor or blood sample is processed and sorted. Thus, one must be able to access a flow cytometer quickly for studies involving human tumor cells. This ensures that each tumor sample is analyzed in a timely and efficient manner, and data from each precious sample is not compromised by delays in processing because of lack of access to a flow cytometer. This is one of many reasons why the Stanford University Stem Cell Institute has established a flow cytometry core for the use of investigators in the Institute. Although commercial flow cytometers are quite sophisticated, they need to be modified for optimal isolation of cells from different tissues. In addition, each of the flow cytometers in this core has been modified so that both hematopoeitic and solid tissue stem cells can be isolated using optimal conditions. This is made possible in part by the core leader, David Parks. Based on Institute user's needs, the flow cytometers receive customized factory components. In addition, factory settings have been modified by the core PI to optimize sorting efficiency of both blood and solid tissue stem cells.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Krampitz, Geoffrey Wayne; George, Benson M; Willingham, Stephen B et al. (2016) Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A 113:4464-9
Weiskopf, Kipp; Schnorr, Peter J; Pang, Wendy W et al. (2016) Myeloid Cell Origins, Differentiation, and Clinical Implications. Microbiol Spectr 4:
Dalerba, Piero; Sahoo, Debashis; Paik, Soonmyung et al. (2016) CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374:211-22
Weiskopf, Kipp; Jahchan, Nadine S; Schnorr, Peter J et al. (2016) CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest 126:2610-20
Feng, Mingye; Chen, James Y; Weissman-Tsukamoto, Rachel et al. (2015) Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A 112:2145-50
Jeong, Youngtae; Swami, Srilatha; Krishnan, Aruna V et al. (2015) Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D. Mol Cancer Ther 14:1951-61
McCracken, Melissa N; Cha, Adriel C; Weissman, Irving L (2015) Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 ""Don't Eat Me"" Signals. Clin Cancer Res 21:3597-601
Cheah, Ming T; Chen, James Y; Sahoo, Debashis et al. (2015) CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A 112:4725-30
Feng, Weiguo; Gentles, Andrew; Nair, Ramesh V et al. (2014) Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells 32:1734-45
Wang, Jianbin; Quake, Stephen R (2014) RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A 111:13157-62

Showing the most recent 10 out of 35 publications